DOCSLIB.ORG

Quantification and Classification of Diclofenac Sodium Content

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quantification and Classification of Diclofenac Sodium Content pharmaceuticals Article Quantification and Classification of Diclofenac Sodium Content in Dispersed Commercially Available Tablets by Attenuated Total Reflection Infrared Spectroscopy and Multivariate Data Analysis Eirini Siozou 1, Vasilios Sakkas 1,* and Nikolaos Kourkoumelis 2 1 Laboratory of Analytical Chemistry, Department of Chemistry, University of Ioannina, 45 110 Ioannina, Greece; [email protected] 2 Department of Medical Physics, School of Health Sciences, University of Ioannina, 45 110 Ioannina, Greece; [email protected] * Correspondence: [email protected]; Tel.: +30-26510-08303; Fax: +30-26510-08795 Abstract: A new methodology, based on Fourier transform infrared spectroscopy equipped with an attenuated total reflectance accessory (ATR FT-IR), was developed for the determination of diclofenac sodium (DS) in dispersed commercially available tablets using chemometric tools such as partial least squares (PLS) coupled with discriminant analysis (PLS-DA). The results of PLS-DA depicted a perfect classification of the tablets into three different groups based on their DS concentrations, while the developed model with PLS had a sufficiently low root mean square error (RMSE) for the prediction of the samples’ concentration (~5%) and therefore can be practically used for any tablet with an Citation: Siozou, E.; Sakkas, V.; Kourkoumelis, N. Quantification and unknown concentration of DS. Comparison with ultraviolet/visible (UV/Vis) spectrophotometry as Classification of Diclofenac Sodium the reference method revealed no significant difference between the two methods. The proposed Content in Dispersed Commercially methodology exhibited satisfactory results in terms of both accuracy and precision while being rapid, Available Tablets by Attenuated Total simple and of low cost. Reflection Infrared Spectroscopy and Multivariate Data Analysis. Keywords: diclofenac sodium; ATR spectroscopy; Fourier transform infrared; quantitative analysis; Pharmaceuticals 2021, 14, 440. chemometrics https://doi.org/10.3390/ph14050440 Academic Editors: Luisa Barreiros and Marcela Segundo 1. Introduction Non-steroidal anti-inflammatory drugs (NSAIDs) are a broad family of compounds Received: 16 March 2021 which are commonly used for the treatment of inflammation and pain. Diclofenac Accepted: 3 May 2021 ([2-(2,6-dichloroanilino)phenyl]acetic acid) is one of the most widely used NSAIDs com- Published: 7 May 2021 monly used for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and musculoskeletal and sports injuries, as well as for the relief of dysmenorrhea and Publisher’s Note: MDPI stays neutral postoperative pain [1–6]. It is typically found as sodium or potassium salt and it is available with regard to jurisdictional claims in in a variety of drug formulations including tablets, capsules, ophthalmic drops, suppos- published maps and institutional affil- iations. itories, and ointments, depending on the site of application. Diclofenac sodium (DS) (Figure1) is primarily used for its anti-inflammatory properties and acts at a slower pace than potassium salt which is readily absorbed by the body and provides instant relief [7]. Quality control of dosage forms plays a major role in pharmaceutical industries, since the products must meet certain criteria set by pharmacopoeias and other authorities; other- Copyright: © 2021 by the authors. wise, they may be substandard and/or even pose a threat to public health. Therefore, the Licensee MDPI, Basel, Switzerland. development of sensitive and reliable methods for the determination of active ingredients This article is an open access article in dosage forms is crucial. The official method for the determination of DS proposed by the distributed under the terms and conditions of the Creative Commons European Pharmacopoeia (Ph.Eur.) and the United States Pharmacopoeia (USP) includes Attribution (CC BY) license (https:// the dispersion of the standard compound in anhydrous acetic acid followed by titration creativecommons.org/licenses/by/ with perchloric acid and potentiometric determination of the endpoint [8,9], while for the 4.0/). Pharmaceuticals 2021, 14, 440. https://doi.org/10.3390/ph14050440 https://www.mdpi.com/journal/pharmaceuticals Pharmaceuticals 2021, 14, x FOR PEER REVIEW 2 of 11 (USP) includes the dispersion of the standard compound in anhydrous acetic acid fol- Pharmaceuticals 2021, 14, 440 2 of 11 lowed by titration with perchloric acid and potentiometric determination of the endpoint [8,9], while for the determination of DS in slow-release tablets, the USP proposes its dis- persiondetermination in a methanol of DS– inwater slow-release mixture tablets,(70:30) theand USP subsequent proposes analysis its dispersion in a liqu in aid methanol– chro- matographwater mixture with a (70:30)UV detector, and subsequent using methanol analysis and inphosphate a liquid buffer chromatograph (pH 2.5) as with mobile a UV phasedetector, components using methanol [10]. In recent and phosphate decades, bufferseveral (pH analytical 2.5) as mobilemethods phase have components been devel- [10]. opedIn recentfor the decades, determination several of analytical diclofenac methods in drug have products, been developed including for spectrophot the determinationometric of [7,11diclofenac–16], spectroscopic in drug products, [17–21], including fluorimetric spectrophotometric [22], potentiometric [7,11 –[2216],–27], spectroscopic and chromato- [17–21], graphicfluorimetric methods [22 [28], potentiometric–34]. [22–27], and chromatographic methods [28–34]. Figure 1. Structure of diclofenac sodium molecule. Figure 1. Structure of diclofenac sodium molecule. Spectroscopic methods have the advantages of a relatively low cost and rapid sample analysis.Spectroscopic Attenuated methods total have reflectance the advantages infrared of spectroscopy a relatively low with cost Fourier and rapid transformation sample analysis.(ATR FT-IR)Attenuated is not t consideredotal reflectance as a quantitativeinfrared spectroscopy technique with by many. Fourier However, transformation ATR FT-IR (ATRhas FT been-IR) used is not before considered as a quantitative as a quantitative technique technique for the by analysis many. of However, NSAIDs asATR an accurate,FT-IR hassensitive, been used and before low-cost as a quantitative technique. technique for the analysis of NSAIDs as an accurate, sensitive,Van and Overbeke low-cost et technique. al. used ATR FT-IR to quantify ketoprofen in pharmaceutical formu- lationsVan Overbeke such as capsules et al. used and ATR injection FT-IR ampoules, to quantify in combination ketoprofen in with pharmaceutical partial least-squares for- mulations(PLS) analysis such as [35 capsules]. Similarly, and Boyerinjection et al.ampoules, proposed in an combination analytical method with partial without least prior- squaressample (PLS) treatment analysis for [35]. the Similarly, determination Boyer of et niflumical. proposed acid an in aanalytical pharmaceutical method gelwithout by ATR FT-IR and PLS calibration with a root mean square error of prediction (RMSEP) equal to prior sample treatment for the determination of niflumic acid in a pharmaceutical gel by 0.2 for the validation set [36]. Lawson et al. examined the potential use of ATR FT-IR to ATR FT-IR and PLS calibration with a root mean square error of prediction (RMSEP) equal provide rapid quantitative analyses of suspect counterfeit tablet formulations containing to 0.2 for the validation set [36]. Lawson et al. examined the potential use of ATR FT-IR to paracetamol [37]. Sensitive methods based on ATR FT-IR spectroscopy were developed provide rapid quantitative analyses of suspect counterfeit tablet formulations containing by Hassib et al. for the quantitative assessment of four NSAIDs, namely, etodolac, tolfe- paracetamol [37]. Sensitive methods based on ATR FT-IR spectroscopy were developed namic acid, bumadizone, and diacerein, by peak profiling using normal or derivative by Hassib et al. for the quantitative assessment of four NSAIDs, namely, etodolac, tolfen- spectroscopy [38]. amic acid, bumadizone, and diacerein, by peak profiling using normal or derivative spec- PLS combined with ATR FT-IR was proposed by Silva et al. for the simultaneous troscopy [38]. determination of the antibiotics sulphamethoxazole and trimethoprim in raw material PLS combined with ATR FT-IR was proposed by Silva et al. for the simultaneous powder mixtures [39]. Kandhro et al. developed a reliable analytical method for the determination of the antibiotics sulphamethoxazole and trimethoprim in raw material quantitative assessment of cefixime in orally administered pharmaceutical formulations powderbased mixtures on ATR FT-IR[39]. Kandhro spectroscopy. et al. developed Standards a were reliable prepared analytical in aqueous method medium for the quan- ranging titativefrom assessment 350 to 6000 of mg/kg cefiximeand in PLS orally regression administered was applied pharmaceutical in the range formulations 1485–887 cm based−1 [40 ]. on Furthermore,ATR FT-IR spectroscopy. ATR FT-IR has Standards also been were used prepared for the determination in aqueous medium of polymorphs ranging in from dosage −1 350forms. to 6000 Salari mg/kg and and Young PLS investigatedregression was the applied feasibility in the of ATRrange FT-IR 1485 for–887 the cm qualitative [40]. Fur- and thermore,quantitative ATR analysisFT-IR has of also mixtures been used of three for knownthe determinat polymorphsion of of polymorphs ganciclovir, in an dosage antiviral forms.compound. Salari
Load more

Recommended publications
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • FORMULATION and EVALUATION of COLON TARGETED PELLETS of BUMADIZONE CALCIUM” Mr
    THESIS ISSN: 2349-2678 Contents lists available at www.ijpba.in International Journal of Pharmaceutical and Biological Science Archive PubMed (National Library of Medicine ID: 101738825) Index Copernicus Value 2017: 71.80 Volume 7 Issue 3; May-June; 2019; Page No. 01-69 “FORMULATION AND EVALUATION OF COLON TARGETED PELLETS OF BUMADIZONE CALCIUM” Mr. Shah Akashkumar Nareshkumar1, Mr. Anil G. Raval2 1PG Research Scholar, Department of Pharmaceutics, Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat 2Assistant Professor, Department of Pharmaceutics, Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat ABSTRACT Aim: The aim of this study was to Formulation and Evaluation of colon targeted pellets of Bumadizone Calcium Objective: Bumadizone Calcium is an acetic acid derivative, having irritation in stomach. Bumadizone Calcium has short half-life (4hrs) and undergoes first pass metabolism. It is pH-dependent. This research work was carried out to improve the bioavailability, patient compliance on oral colon targeted drug delivery. Bumadizone Calcium sustained release enteric coated pellets were prepared, which minimize the release of drug in stomach for treatment of IBD formulated by Extrusion Spheronization process. Experimental work done: Enteric coated pellets prepared by Extrusion Spheronization technique. Eudragit S100, HPMC, PVP K30, and Ethyl Cellulose were used as rate controlling polymers. In this study, a pH dependent colon targeted enteric coated pellets was established using 32 full factorial design by giving enteric coating with Eudragit S100. Different Concentration of Eudragit S100 as an enteric coating material (4%, 5%, & %6) and PVP K30 as a Binder (0.5%, 1% & 1.5%) are taken for the measurements of % Drug Release that are performed by using USP dissolution 1 (Basket type) at 50 rpm.
    [Show full text]
  • Søgeprotokol for Nationale Kliniske Retningslinjer
    Søgeprotokol for nationale kliniske retningslinjer Projekttitel/aspekt NKR behandling af patienter med lumbal spinalstenose – Søgning efter primærlitteratur Fagkonsulent /projektleder Rikke Rousing / Maria Herlev Ahrenfeldt Søgespecialist Kirsten Birkefoss Senest opdateret 23.12.2016 Fokuserede spørgsmål Bør patienter med lumbal spinalstenose have tilbudt aktiv PICO 1: behandling i form af superviseret træning fremfor vanlig behandling? PICO 2: Bør patienter med lumbal spinalstenose have tilbudt ledmobiliserende behandling frem for vanlig behandling? PICO 3: Bør patienter med lumbal spinalstenose have tilbudt paracetamol frem for ingen smertestillende behandling? PICO 4: Bør patienter med lumbal spinalstenose have tilbudt non steroid antiinflammatorisk medicin (NSAID) frem for ingen smertestillende behandling? PICO 5: Bør patienter med lumbal spinalstenose have tilbudt smertestillende medicin i form af opioider i tillæg til eventuel behandling med svage smertestillende? PICO 6: Bør patienter med lumbal spinalstenose have tilbudt muskelrelaxantia i tillæg til eventuel behandling med svage smertestillende? PICO 7: Bør patienter med lumbaspinalstenose have tilbudt medicin for neuropatiske smerter? PICO 8: Bør patienter med lumbal spinalstenose have tilbudt kirurgisk dekompression i tilfælde af manglende effekt af ikke kirurgisk behandling? PICO 9: Bør patienter med lumbal spinalstenose have tilbudt stivgørende operation med eller uden instrumentering i tillæg til dekompression? PICO 10: Bør patienter opereret for lumbal spinalstenose tilbydes
    [Show full text]
  • Bumadizone Calcium Dihydrate Microspheres Compressed Tablets for Colon Targeting: Formulation, Optimization and in Vivo Evaluation in Rabbits
    http://informahealthcare.com/drd ISSN: 1071-7544 (print), 1521-0464 (electronic) Drug Delivery, Early Online: 1–12 ! 2014 Informa Healthcare USA, Inc. DOI: 10.3109/10717544.2014.889779 RESEARCH ARTICLE Bumadizone calcium dihydrate microspheres compressed tablets for colon targeting: formulation, optimization and in vivo evaluation in rabbits Samia A. Nour, Nevine Shawky Abdelmalak, and Marianne J. Naguib Faculty of Pharmacy, Department of Pharmaceutics, Cairo University, Cairo, Egypt Abstract Keywords The objective of this study was the development of a colon-targeted microspheres which were Bumadizone calcium, colon targeting, compressed into tablets containing the non-steroidal anti-inflammatory bumadizone calcium histopathology, microspheres compressed 2 dihydrate. A 3 full factorial design was adopted for the evaluation of the prepared into tablets, myeloperoxidase activity, microspheres. The effect of two independent variables namely polymer type (Eudragit RS100, pharmacokinetic parameters ethyl cellulose and cellulose acetate butyrate), and drug: polymer ratio (1:1, 9:1 and 18:1) was studied on the entrapment efficiency and in vitro drug release for 12 h. Colon targeting aims History to minimize the release of the drug off target area (pH 1.2 and 6.8) and to maximize the release of the drug in target area (pH 7.4). Candidate formulae were compressed into core tablets Received 12 January 2014 and colon targeting was achieved using the enzyme-dependent polymer (pectin) as coat in Revised 26 January 2014 three different concentrations 50, 75 and 90%. Candidate formula F15 (microspheres prepared Accepted 28 January 2014 using BDZ:CAB in a ratio of 18:1 and compressed into tablets using 50% pectin and 50% Avicel in the coat) was able to adequately modulate drug release avoiding drug release in the gastric ambient, and reaching the colonic targeting where 99.7% release was achieved within 12 h following zero-order model.
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T (51) International Patent Classification: (74) Common Representative: UNIVERSITY OF VETER¬ A61K 9/06 (2006.01) A61K 47/32 (2006.01) INARY AND PHARMACEUTICAL SCIENCES A61K 9/14 (2006.01) A61K 47/38 (2006.01) BRNO FACULTY OF PHARMACY; University of A61K 47/10 (2006.01) A61K 9/00 (2006.01) Veterinary and Pharmaceutical Sciences Brno Faculty Of A61K 47/18 (2006.01) Pharmacy, Palackeho 1/3, CZ-61242 Brno (CZ). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/CZ20 12/000073 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) Date: International Filing BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 2 August 2012 (02.08.2012) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, 201 1-495 11 August 201 1 ( 11.08.201 1) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 2012- 72 1 February 2012 (01.02.2012) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 2012-5 11 26 July 2012 (26.07.2012) ZW.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]
  • Method and Use for Increasing Efficacy of Anti-Adhesive Compositions in Controlling Inflammation and Pain
    (19) & (11) EP 2 465 513 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 20.06.2012 Bulletin 2012/25 A61K 31/77 (2006.01) A61K 33/06 (2006.01) A61K 45/06 (2006.01) A61P 29/00 (2006.01) (21) Application number: 11195175.2 (22) Date of filing: 12.11.2007 (84) Designated Contracting States: (72) Inventor: Chamness, Kathy L. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Memphis, TN 38104-5305 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (74) Representative: O’Connell, Maura et al FRKelly (30) Priority: 13.11.2006 US 598397 27 Clyde Road Ballsbridge (62) Document number(s) of the earlier application(s) in Dublin 4 (IE) accordance with Art. 76 EPC: 07864257.6 / 2 104 505 Remarks: •This application was filed on 22-12-2011 as a (71) Applicant: Warsaw Orthopedic, Inc. divisional application to the application mentioned Warsaw, IN 46581 (US) under INID code 62. •Claims filed after the date of filing of the application (Rule 68(4) EPC). (54) Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain (57) The invention discloses a method and kit thereof prising an effective amount of at least one pharmaceuti- for increasing the efficiency of anti-adhesive composi- cally-acceptable anti-adhesive non-ionic polymer to a tions by parenterally administering a composition com- site of injury, controlling inflammation at the site of injury, and reducing pain. EP 2 465 513 A2 Printed by Jouve, 75001 PARIS (FR) EP 2 465 513 A2 Description FIELD OF THE INVENTION 5 [0001] The present invention relates to methods of increasing efficacy of anti-adhesive compositions by parental administration of compositions containing anti-adhesive polymers and magnesium salts.
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • Analytical Study of Selected Anti-Inflammatory Drugs
    Analytical Study of Selected Anti-Inflammatory Drugs Thesis Presented by Enas Taha Abdelhamed M.Sc. in Pharmaceutical Sciences Pharmaceutical Chemistry Faculty of Pharmacy - Cairo University 2012 Submitted for The Degree of Doctor of Philosophy In Pharmaceutical Sciences (Pharmaceutical Chemistry) Under the supervision of Prof. Dr. Sonia Talat Hassib Professor of Pharmaceutical Chemistry Faculty of Pharmacy - Cairo University Prof. Dr. Ghaneya Sayed Hassan Professor of Pharmaceutical Chemistry Faculty of Pharmacy - Cairo University Prof. Dr. Asmaa Ahmed El-Zaher Professor of Pharmaceutical Chemistry Faculty of Pharmacy - Cairo University Dr. Marwa Ahmed Fouad Associate Professor of Pharmaceutical Chemistry Faculty of Pharmacy - Cairo University Faculty of Pharmacy Cairo University 2018 Abstract Four simple, accurate, sensitive and economic Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopic (ATR-FTIR) methods have been developed for the quantitative estimation of some non-steroidal anti- inflammatory drugs alone or in presence of related substances. The first method involves the determination of etodolac by direct measurement of the absorbance at 1716 cm-1. In the second method, the second derivative of the IR spectra of tolfenamic acid and its imperity (2-chlorobenzoic acid) was used and the amplitudes were measured at 1084.27 cm-1 and 1058.02 cm-1 for tolfenamic acid and 2-chlorobenzoic acid, respectively. The third method used the first derivative of the IR spectra of bumadizone and its reported degradation product, N,N-diphenylhydrazine and the amplitudes were measured at 2874.98 cm-1 and 2160.32 cm-1 for bumadizone and N,N-diphenylhydrazine, respectively. The fourth method depends on measuring the amplitude of diacerein at 1059.18 cm-1 and of rhein, its reported degradation product, at 1079.32 cm-1 in their first derivative spectra.
    [Show full text]